Pisa Federica Edith, Reinold Jonas, Kollhorst Bianca, Haug Ulrike, Schink Tania
Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Department of Biometry and Data Management, Leibniz Institute for Prevention Researchand Epidemiology - BIPS, Bremen, Germany.
Clin Epidemiol. 2020 Jun 22;12:667-678. doi: 10.2147/CLEP.S222888. eCollection 2020.
To determine the risk of hip-pelvis and other non-vertebral fractures in older adults using antidepressants (ADs).
We conducted a case-control study nested in a cohort of new users of ADs aged ≥65 years without prior hip-pelvis or other non-vertebral fractures, identified in the German Pharmacoepidemiological Research Database (GePaRD) during 2005-2014. Cases were patients first hospitalized for hip-pelvis or other non-vertebral fractures. Up to 100 controls per case were selected using incidence density sampling. AD use was ascertained at index date (ID) based on the supply of last dispensing. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression with current users of mirtazapine as reference (active comparator).
A total of 39,853 cases of hip-pelvis fracture (80% women, median age 81 years) and 31,577 cases of other fractures (84% women, median age 79 years) were matched to >3 million controls. For hip-pelvis fracture, aORs in current users were about 1.3 with little variation between individual ADs, ranging from 1.33 for citalopram (95% CI 1.27-1.39) to 1.28 for amitriptyline (1.21-1.35). For other fractures, the aORs were highest in current users of citalopram (1.50; 1.42-1.58) and duloxetine (1.54; 1.39-1.71) and lowest for amitriptyline (1.18; 1.11-1.26) and trimipramine (1.16; 1.03-1.29). For all examined ADs, the aORs were higher for other fractures than for hip-pelvis fracture.
The risk of fractures varies between ADs, but for most agents is higher than the risk for mirtazapine. When treating older adults with ADs, prescribers should carefully consider the risk profile of individual ADs regarding fractures, which are a major health problem in this population.
确定使用抗抑郁药(ADs)的老年人发生髋骨盆及其他非椎体骨折的风险。
我们在2005 - 2014年德国药物流行病学研究数据库(GePaRD)中识别出的≥65岁且无既往髋骨盆或其他非椎体骨折的ADs新使用者队列中进行了一项病例对照研究。病例为首次因髋骨盆或其他非椎体骨折住院的患者。采用发病密度抽样,为每个病例选取多达100名对照。根据最后一次配药供应情况在索引日期(ID)确定ADs的使用情况。以米氮平的当前使用者作为对照(活性比较剂),使用条件逻辑回归估计调整后的优势比(aORs)和95%置信区间(CIs)。
总共39,853例髋骨盆骨折病例(80%为女性,中位年龄81岁)和31,577例其他骨折病例(84%为女性,中位年龄79岁)与超过300万对照进行了匹配。对于髋骨盆骨折,当前使用者的aORs约为1.3,各ADs之间差异不大,从西酞普兰的1.33(95%CI 1.27 - 1.39)到阿米替林的1.28(1.21 - 1.35)。对于其他骨折,西酞普兰(1.50;1.42 - 1.58)和度洛西汀(1.54;1.39 - 1.71)的当前使用者的aORs最高,而阿米替林(1.18;1.11 - 1.26)和曲米帕明(1.16;1.03 - 1.29)的最低。对于所有检测的ADs,其他骨折的aORs高于髋骨盆骨折。
不同ADs导致骨折的风险各异,但大多数药物的风险高于米氮平。在使用ADs治疗老年人时,处方者应仔细考虑各ADs在骨折方面的风险概况,骨折是该人群中的一个主要健康问题。